Tempus AI Q1 2026 Revenue Hits $348.1M, Up 36% YoY
Tempus AI (NASDAQ:TEM) reported Q1 2026 revenue of $348.1 million, up over 36% year-over-year, with growth across diagnostics and data segments. The company raised its full-year outlook.
Key Numbers
Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, driven by growth in both its diagnostics and data and applications segments. The company also raised its full-year guidance.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $348.1M | ~$256.0M | +36% |
| Net Income | Not disclosed | Not disclosed | - |
| EPS | Not disclosed | Not disclosed | - |
Highlights from the Call
Founder and CEO Eric Lefkofsky noted that diagnostics revenue grew strongly, driven by increased volumes of genetic and cancer tests. The data and applications segment also saw growth due to rising demand for AI solutions in healthcare.
Guidance
Tempus AI raised its full-year 2026 revenue guidance, though specific figures were not provided.
Stock Impact
No direct stock reaction was mentioned, but the strong growth and raised guidance are likely to boost investor confidence.
What This Means for Investors
Tempus AI's solid Q1 performance demonstrates its ability to sustain growth in the AI-driven healthcare sector. The raised guidance reflects management's confidence in continued momentum, potentially making the stock attractive for investors seeking exposure to health tech.
Frequently Asked Questions
Found this useful? Share it